fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Presentation from the ESC Congress 2013 – SAVOR-TIMI 53 Trial

Written by | 26 Sep 2013 | All Medical News

by Deepak Bhatt (pictured right), Other authors: Dr. Benjamin M. Scirica, USA; Prof. Eugene Braunwald, USA; Prof. Itamar Raz, Israel; on behalf of the SAVOR-TIMI 53 Steering Committee and Investigators.
Background:
Worldwide projections estimate that the prevalence of Type 2 diabetes mellitus(T2DM) will increase to more than 400 million people by 2030, largely due to a dramatic increase in the developing world. Despite decades of clinical research, no particular strategy or anti-diabetic agent has been shown to reduce cardiovascular (i.e., macrovascular) risk. In addition, there remains a concern regarding the cardiovascular (CV) safety of anti-diabetic drugs. Therefore a strong clinical need exists for antidiabetic agents that are safe and effectively reduce CV risk. Saxagliptin, a DPP-4 inhibitor, improves glycemic control by potentiating endogenous glucagon-like peptide (GLP)-1 concentrations, which augment insulin secretion and decrease glucagon release.

Methods:
SAVOR-TIMI 53 is a phase 4, randomized, double-blind, placebo-controlled, trial designed to evaluate the safety and efficacy of saxagliptin during long-term treatment of  ~16,500 patients with T2DM. Eligible patients with HbA1c >=6.5% and <12.0% on any background antidiabetic treatment (except incretin therapy) and history of established cardiovascular disease (history of coronary, cerebral, or peripheral artery disease) or multiple cardiovascular risk factors, were randomized 1:1 to saxagliptin 5mg qd (2.5mg in subjects with moderate/severe renal dysfunction) or matching placebo, stratified by qualifying disease state. The primary end point is the composite of CV death, non-fatal myocardial infarction, or non-fatal ischemic stroke. Major secondary end points include expanded MACE and total death. CV endpoints are prospectively adjudicated by a blinded events committee. The targeted number of primary endpoint events (n=1040) was accrued in January, 2013. Trial registration – NCT01107886 (www.clinicaltrials.gov).

Results:
Between May, 2010 and December, 2011, 16,497 subjects with T2DM and established cardiovascular disease (78% of the population) or multiple cardiovascular risks factors alone (22%) were randomized at 779 sites in 26 countries. The mean age was 65 years, 67% of patients were male, and the median duration of T2DM at randomization was 11.9 years. Database lock is anticipated to occur in June, allowing presentation of final results at ESC.

Conclusions:
1040 primary endpoint events provides 85% power to identify a 17% relative reduction of the primary endpoint with saxagliptin vs. placebo, and 98% power to test for non-inferiority of saxagliptin vs. placebo (reject the upper limit of 95% CI for a hazard ratio <1.3 at a one-sided α of 0.025). SAVOR-TIMI 53 is testing the hypothesis that treatment with saxagliptin is safe and reduces cardiovascular events in T2DM patients with established cardiovascular disease or multiple cardiac risk factors.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.